Rash from EGFR inhibitors: Opportunities and challenges for palliation
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11912-008-0048-1.pdf
Reference26 articles.
1. Giusti RM, Shastri KA, Cohen MH, et al.: FDA drug approval summary: panitumumab. Oncologist 2007, 12:577–583.
2. Johnson JR, Cohen M, Sridhara R, et al.: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005, 11:6414–6421.
3. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960–1966.
4. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer. Cancer Biol Ther 2006, 5:340–342.
5. Patiyil S, Chan SN, Jatoi A: New agents, new rashes: an update on skin complications from cancer chemotherapy. Curr Oncol Rep 2006, 8:269–274.
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors;mAbs;2021-01-01
2. Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report;Yonago Acta Medica;2020
3. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab;PLOS ONE;2018-12-17
4. Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors;OncoTargets and Therapy;2016-04
5. Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules;Current Drug Metabolism;2011-12-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3